Summary & Overview
HCPCS Level II J0872: Daptomycin (Xellia) Injection, 1 mg
HCPCS Level II code J0872 identifies a 1 mg unit of daptomycin (Xellia) supplied unrefrigerated and noted as not therapeutically equivalent to J0878 or J0873. This billing code matters nationally because it determines how facilities and clinicians report and bill for a specific branded injectable antibiotic product, with implications for reimbursement, drug inventory control, and clinical documentation across inpatient and outpatient infusion settings. Major national payers commonly involved in coverage decisions for parenteral antimicrobials include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will learn what the code represents clinically and operationally, the typical sites of service where this code applies, and the scope of payer coverage addressed in the analysis. The publication also provides benchmarks and contextual information about billing practice for single-drug injectable codes, notes on equivalency distinctions called out in the code description, and guidance on where to find related coding entries. Data not available in the input: specific payer policies, associated taxonomies, ICD-10 pairings, and related codes.
Billing Code Overview
HCPCS Level II code J0872 describes an injectable formulation of daptomycin (Xellia), supplied unrefrigerated, 1 mg, and specifies that it is not therapeutically equivalent to J0878 or J0873. The code denotes the drug product and unit of measure used for billing parenteral antimicrobial therapy.
-
Service type: Injectable antimicrobial administration (drug supply)
-
Typical site of service: Outpatient infusion centers, hospital inpatient pharmacies, emergency departments, and other settings where parenteral antibiotics are administered
Clinical & Coding Specifications
Clinical Context
A 62-year-old hospitalized patient with a history of chronic kidney disease and recent complicated skin and soft tissue infection is ordered intravenous daptomycin due to suspected methicillin-resistant Staphylococcus aureus (MRSA) bacteremia after failure or intolerance of vancomycin. The pharmacy dispenses J0872 (daptomycin, unrefrigerated, 1 mg unit) for inpatient administration. Nursing verifies weight-based dosing, prepares the appropriate mg dose using the supplied vial strength, and administers via slow intravenous push or infusion per institutional protocol. Serum creatine phosphokinase (CPK) is monitored at baseline and periodically during therapy. The patient receives doses in a hospital acute care bed; if transitioned to an observation stay or skilled nursing facility with IV antibiotic services, the same HCPCS code is used for billing per payor guidelines. Documentation includes indication, dose calculation, lot number, route, time of administration, patient tolerance, and any adverse events such as myopathy or eosinophilic pneumonia.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier | Routine reporting when no modifier applies |
22 |